BR Biopharma, Inc. (NASDAQ:BRBI) Sees Large Decrease in Short Interest

BR Biopharma, Inc. (NASDAQ:BRBI) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,225 shares, a decline of 65.4% from the August 15th total of 3,543 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 1,065 shares, the days-to-cover ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of BR Biopharma in a research report on Tuesday, September 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

BR Biopharma Stock Performance

BRBI traded down $0.02 during trading on Monday, reaching $11.18. 101 shares of the stock were exchanged, compared to its average volume of 3,340. BR Biopharma has a twelve month low of $9.09 and a twelve month high of $67.01. The stock has a market cap of $132.04 million and a P/E ratio of 139.75. The stock’s 50 day moving average price is $10.82 and its two-hundred day moving average price is $12.74.

BR Biopharma (NASDAQ:BRBI) last issued its earnings results on Tuesday, June 30th. The company reported $0.09 EPS for the quarter. The business had revenue of $25.13 million for the quarter.

BR Biopharma Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 4th. Stockholders of record on Monday, August 17th were given a $0.1415 dividend. This represents a $0.57 dividend on an annualized basis and a dividend yield of 5.1%. The ex-dividend date was Monday, August 17th. BR Biopharma’s payout ratio is presently 525.00%.

Institutional Investors Weigh In On BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma comprises about 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th biggest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.